Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Onvansertib with cytarabine or decitabine for R/R AML

Amer Zeidan • 6 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Cytarabine Decitabine Onvansertib

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the ongoing phase 1b dose-escalation trial (NCT03303339) evaluating the safety, efficacy and correlative analyses of onvansertib, a PLK-1 inhibitor, in combination with either low-dose cytarabine or decitabine in relapsed/refractory acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Amer Zeidan

Current best practices and emerging treatment strategies in higher-risk MDS
16:43
Current best practices and emerging treatment strategies in higher-risk MDS
Amer Zeidan et al. • 3 Oct 2026
Long-term results from KOMET-007: ziftomenib with 7+3 in newly diagnosed NPM1-m or KMT2A-r AML
2:11
Long-term results from KOMET-007: ziftomenib with 7+3 in newly diagnosed NPM1-m or KMT2A-r AML
Amer Zeidan • 14 Jun 2026
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
36:15
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
Amer Zeidan et al. • 19 Mar 2026
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
1:10
Correlation between treatment-emergent cytopenias and clinical response with imetelstat in LR-MDS
Amer Zeidan • 5 Dec 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals